Multiplex proteomic approaches to sepsis research: Case studies employing new technologies

Expert Review of Proteomics

Volumn 2, Issue 5, 2005, Pages 669-680

  Heuer, Josef G ^a   Cummins, David J ^a   Edmonds, Brian T ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly Corporate Center   (United States)

Author keywords

Activated protein C; Antibody protein array; Cecal ligation puncture; Drotrecogin; Luminex ; Multiplex; Proteomics; Sepsis; Systems biology; Xigris

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; DROTRECOGIN; PHOSPHOTRANSFERASE INHIBITOR;

CLINICAL FEATURE; COST OF ILLNESS; DIAGNOSTIC TEST; DISEASE COURSE; HUMAN; INTENSIVE CARE; MEDICAL DECISION MAKING; NONHUMAN; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; SEPSIS;

ANIMALS; BIOMEDICAL RESEARCH; HUMANS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; SEPSIS;

EID: 27144556072     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2.5.669     Document Type: Review

References (76)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 20, 864-874 (1992).
2. Levy M, Fink M, Marshall J et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference. Crit. Care Med. 31, 1250-1256 (2003).
3. Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29(7), 1303-1310 (2001). Benchmark study for the impact of sepsis on the health care system.
4. Alberti C, Brun-Buisson C, Burchardi H et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 28(2), 108-121 (2002).
5. Centers for Disease Control and Prevention. Increase in national hospital discharge survey rates for septicemia. MMWR 39, 31-34 (1990).
6. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time? Crit. Care Med. 26(12), 2078-2086 (1998).
7. Rivers E, Nguyen B, Havstad S et al. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 345(19), 1368-1377 (2001).
8. Haley M, Cui X, Minneci PC et al. Recombinant human activated protein C in sepsis: previous concerns and current usage. Therapy 1(1), 123-129 (2004). Overview of the only US Food and Drug Administration-approved therapeutic for severe sepsis.
9. Nguyen A, Yaffe MB. Proteomics and systems biology approaches to signal transduction in sepsis. Crit. Care Med. 31(1 Suppl.), S1-S6 (2003). Excellent overview of a systems biology approach to sepsis.
10. Puneet P, Moochhala S, Bhatia M. Chemokines in acute respiratory distress syndrome. Am. J. Physiol. Lung Cell Mol. Physiol. 288(1), L3-L15 (2005).
11. Roos D, van Bruggen R, Meischl C. Oxidative killing of microbes by neutrophils. Microbes Infect. 5(14), 1307-1315 (2003).
12. Cook DN, Pisetsky DS, Schwartz DA. Toll-like receptors in the pathogenesis of human disease. Nature Immunol. 5(10), 975-979 (2004).
13. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 101(10), 3765-3777 (2003).
14. Grandel U, Grimminger F. Endothelial responses to bacterial toxins in sepsis. Crit. Rev. Immunol. 23(4), 267-299 (2003).
15. Young JD. The heart and circulation in severe sepsis. Br. J. Anaesth. 93(1), 114-120 (2004).
16. Gibot S, Levy B, Neviere R et al. Myocardial dysfunction and septic shock, Med. Sci (Paris) 20(12), 1115-1118 (2004).
17. Esmon CT, Fukudome K, Mather T et al. Inflammation, sepsis, and coagulation. Haematologica 84(3), 254-259 (1999).
18. Jagneaux T, Taylor DE, Kantrow SP. Coagulation in sepsis. Am. J. Med. Sci. 328(4), 196-204 (2004).
19. Strassheim D, Park JS, Abraham E. Sepsis: current concepts in intracellular signaling. Int. J. Biochem. Cell Biol. 34(12), 1527-1533 (2002).
20. Akira S, Takeda K. Toll-like receptor signalling. Nature Rev. Immunol. 4(7), 499-511 (2004).
21. Scott MJ, Godshall CJ, Cheadle WG. Jaks, STATs, cytokines, and sepsis. Clin. Diagn. Lab. Immunol. 9(6), 1153-1159 (2002).
22. Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Ann. Rev. Genomics Hum. Genet. 2, 343-372 (2001).
23. Weston AD, Hood L. Systems biology, proteomics, and the future of healthcare: toward predictive, preventative, and personalized medicine. J. Proteome Res. 3(2), 179-196 (2004). Excellent review of proteomics and systems biology analysis.
24. Gygi SP, Aebersold R. Mass spectrometry and proteomics. Curr. Opin. Chem. Biol. 4(5), 489-494 (2000).
25. Reinders J, Lewandrowski U, Moebius J et al. Challenges in mass spectrometry-based proteomics. Proteomics 4(12), 3686-3703 (2004). Update on where the evolution of mass spectrometry applied to proteomics is headed.
26. Monteoliva L, Albar JP. Differential proteomics: an overview of gel and non-gel based approaches. Brief Funct. Genomic Proteomic 3(3), 220-239 (2004).
27. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 4(12), 3665-3685 (2004).
28. Turecek F. Mass spectrometry in coupling with affinity capture-release and isotope-coded affinity tags for quantitative protein analysis. J. Mass Spectrom. 37(1), 1-14 (2002).
29. Mo W, Karger BL. Analytical aspects of mass spectrometry and proteomics. Curr. Opin. Chem. Biol. 6(5), 666-675 (2002).
30. Leitner A, Lindner W. Current chemical tagging strategies for proteome analysis by mass spectrometry. J. Chromatogr. BAnalyt. Technol. Biomed. Life Sci. 813(1-2), 1-26 (2004).
31. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 563(Pt 1), 23-60 (2005). Excellent discussion of the issues facing protein biomarkers in clinical medicine.
32. Cooper JW, Wang Y, Lee CS. Recent advances in capillary separations for proteomics. Electrophoresis 25(23-24), 3913-3926 (2004).
33. Huang YH, Chang AY, Huang CM et al. Proteomic analysis of lipopolysaccharide-induced apoptosis in PC12 cells. Proteomics 2(9), 1220-1228 (2002).
34. Kaiser T, Kamal H, Rank A et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 104(2), 340-349 (2004).
35. Fulton RJ, McDade RL, Smith PL et al. Advanced multiplexed analysis with the FlowMetrix system. Clin. Chem. 43(9), 1749-1756 (1997). First report of the widely successful Luminex® bead-based multiplexing platform.
36. Vignali DA. Multiplexed particle-based flow cytometric assays. J. Immunol. Methods. 243(1-2), 243-255 (2000).
37. Templin MF, Stoll D, Schrenk M et al. Protein microarray technology. Drug Discov. Today 7(15), 815-822 (2002).
38. Templin MF, Stoll D, Bachmann J, Joos TO. Protein microarrays and multiplexed sandwich immunoassays: what beats the beads? Comb. Chem. High Throughput Screen. 7(3), 223-229 (2004).
39. Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2(2), RESEARCH0004 (2001). First report on 2D protein microarrays.
40. Melton L. Protein arrays: proteomics in multiplex. Nature 429(6987), 101-107 (2004). Excellent overview of protein array technology platform.
41. Yingyongnarongkul BE, How SE, Diaz-Mochon JJ et al. Parallel and multiplexed bead-based assays and encoding strategies. Comb. Chem. High Throughput Screen. 6(7), 577-587 (2003).
42. Haab BB, Zhou H. Multiplexed protein analysis using spotted antibody microarrays. Methods Mol. Biol. 264, 33-45 (2004).
43. Barry R, Soloviev M. Quantitative protein profiling using antibody arrays. Proteomics 4(12), 3717-3726 (2004).
44. Schweitzer B, Roberts S, Grimwade B et al. Multiplexed protein profiling on microarrays by rolling-circle amplification. Nature Biotechnol. 20(4), 359-365 (2002).
45. Yuk JS, Jung SH, Jung JW et al. Analysis of protein interactions on protein arrays by a wavelength interrogation-based surface plasmon resonance biosensor. Proteomics 4(11), 3468-3476 (2004).
46. Ray CA, Bowsher RR, Smith WC et al. Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. J. Pharm. Biomed. Anal. 36(5), 1037-1044 (2005). Stresses the importance of rigorous optimization and validation in multiplex assay development.
47. Bock C, Coleman M, Collins B et al. Photoaptamer arrays applied to multiplexed proteomic analysis. Proteomics 4(3), 609-618 (2004).
48. Renberg B, Shiroyama I, Engfeldt T et al. Affibody protein capture microarrays: synthesis and evaluation of random and directed immobilization of affibody molecules. Anal. Biochem. 341(2), 334-343 (2005).
49. Oliver KG, Kettman JR, Fulton RJ. Multiplexed analysis of human cytokines by use of die FlowMetrix system. Clin. Chem. 44(9), 2057-2060 (1998).
50. Prabhakar U, Eirikis E, Reddy M et al. Validation and comparative analysis of a multiplexed assay for the simultaneous quantitative measurement of Th1/Th2 cytokines in human serum and human peripheral blood mononuclear cell culture supernatants. J. Immunol. Methods 291(1-2), 27-38 (2004).
51. de Jager W, te Velthuis H, Prakken BJ et al. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin. Diagn. Lab. Immunol. 10(1), 133-139 (2003).
52. Knight PR, Sreekumar A, Siddiqui J et al. Development of a sensitive microarray immunoassay and comparison with standard enzyme-linked immunoassay for cytokine analysis. Shock 21(1), 26-30 (2004).
53. Zhou H, Bouwman K, Schotanus M et al. Two-color, rolling-circle amplification on antibody microarrays for sensitive, multiplexed serum-protein measurements. Genome Biol. 5(4), R28 (2004).
54. Khan SS, Smith MS, Reda D et al. Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin. Cytom. 61(1), 35-39 (2004).
55. Kader HA, Tchernev VT, Satyaraj E et al. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-β1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am. J. Gastroenterol. 100(2), 414-423 (2005). Demonstrates the clinical utility of protein arrays for biomarker identification.
56. Perlee L, Christiansen J, Dondero R et al. Development and standardization of multiplexed antibody microarrays for use in quantitative proteomics. Proteome Sci. 2(1), 9 (2004).
57. Valkirs G. Protein arrays that actually work: successful validation and deployment of biomarker panels. Presented at Cambridge Health Tech Molecular Medicine Tri-conference, CA, USA 22 April (2005). Protein arrays can be produced for the critical care clinical diagnostic setting.
58. Bejamini, Y, Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Royal Stat. Soc. B 57, 289-300(1995).
59. Amaratunga D, Cabrera J. Exploration and Analysis of DNA Microarray and Protein Array Data. John Wiley & Sons, NJ, USA, 60-82 (2004). Excellent discussion regarding protein array data analysis. See http://media.wiley. com/product_data/excerpt/88/04712739/0471273988.pdf and www.wiley.com/WileyCDA/ WileyTitle/productCd-0471273988,descCd-tableOfContents.html
60. Newby LK, Storrow AB, Gibier WB et al. Bedside multimarker testing for risk stratification in chest pain units. The Chest Pain Evaluation by Creatine Kinase-MB, Myoglobin, and Troponin I (CHECKMATE) Study. Circulation 103(14), 1832-1837 (2001).
61. Kettman JR, Davies T, Chandler D et al. Classification and properties of 64 multiplexed microsphere sets. Cytometry 33(2), 234-243 (1998).
62. Cirillo PF, Pargellis C, Regan J. The non-diaryl heterocycle classes of p38 MAPK inhibitors. Curr. Top. Med. Chem. 2(9), 1021-1035 (2002).
63. Duncia JV, Santella JB III, Higley CA et al. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg. Med. Chem. Lett. 8(20), 2839-2844 (1998).
64. Dumont FJ, Staruch MJ, Fischer P et al. Inhibition of T-cell activation by pharmacologic disruption of the MEK1/ERK MAPK or calcineurin signaling pathways results in differential modulation of cytokine production. J. Immunol. 160(6), 2579-289 (1998).
65. Agarwal MK. Assessment of the nature of reticuloendothelial contribution during endotoxicosis in mice. J. Reticuloendothel. Soc. 12(1), 40-52 (1972).
66. Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock - a review of laboratory models and a proposal. J. Surg. Res. 29(2), 189-201 (1980).
67. Baker CC, Chaudry IH, Gaines HO, Baue AE. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94(2), 331-335 (1983).
68. Heuer JG, Bailey DL, Sharma GR et al. Cecal ligation and puncture with total parenteral nutrition: a clinically relevant model of the metabolic, hormonal, and inflammatory dysfunction associated with critical illness. J. Surg. Res. 121(2), 178-186 (2004).
69. Duan X, Yarmush DM, Berthiaume F et al. A mouse serum two-dimensional gel map: application to profiling burn injury and infection. Electrophoresis 25(17), 3055-3065 (2004).
70. Tiao GM, Hudson K, Lieberman MA et al. Identification of altered gene expression in skeletal muscle during sepsis using differential display. J. Surg. Res. 64(1), 63-67 (1996).
71. Hsieh YC, Hsu C, Yang RC et al. Isolation of bonafide differentially expressed genes in the 18-hour sepsis liver by suppression subtractive hybridization. Shock 21(6), 549-555 (2004).
72. Chinnaiyan AM, Huber-Lang M, Kumar-Sinha C et al. Molecular signatures of sepsis: multiorgan gene expression profiles of systemic inflammation. Am. J. Pathol. 159(4), 1199-1209 (2001).
73. Cobb JP, Laramie JM, Stormo GD et al. Sepsis gene expression profiling: murine splenic compared with hepatic responses determined by using complementary DNA microarrays. Crit. Care Med. 30(12), 2711-2721 (2002).
74. Higgins MA, Berridge BR, Mills BJ et al. Gene expression analysis of the acute phase response using a canine microarray. Toxicol. Sci. 74(2), 470-484 (2003).
75. Fannin RD, Auman JT, Bruno ME et al. Differential gene expression profiling in whole blood during acute systemic inflammation in lipopolysaccharide-treated rats. Physiol. Genomics 21(1), 92-104 (2005).
76. Heuer JG, Sharma GR, Gerlitz B et al. Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis. Crit. Care Med. 32(7), 1570-1578 (2004). Excellent example of translational sepsis research across preclinical and human model systems using multiplex proteomics.